메뉴 건너뛰기




Volumn 8, Issue 2, 2013, Pages 143-153

Targeted drug delivery for breast cancer treatment

Author keywords

Breast cancer; Metastasis; Stem cells; Targeted drug delivery; Treatment; Tumor

Indexed keywords

ALENDRONIC ACID; ALPHA FETOPROTEIN; ANGIOGENESIS INHIBITOR; ANTINEOPLASTIC AGENT; BEVACIZUMAB; COMBRETASTATIN; DOCETAXEL; DOXORUBICIN; DRUG CARRIER; EPIDERMAL GROWTH FACTOR RECEPTOR 2; ESTROGEN RECEPTOR; FULVESTRANT; LIPOCORTIN 2; MONOCYTE CHEMOTACTIC PROTEIN 1; NANOPARTICLE; NICOTINAMIDE ADENINE DINUCLEOTIDE ADENOSINE DIPHOSPHATE RIBOSYLTRANSFERASE INHIBITOR; OXALIPLATIN; PACLITAXEL; PEPTIDE DERIVATIVE; POLYMER; PROGESTERONE RECEPTOR; PROTEIN KINASE C; PROTEIN KINASE C INHIBITOR; TAMOXIFEN; TRANSCRIPTION FACTOR PAX2; TRASTUZUMAB; UNINDEXED DRUG; VADIMEZAN; VASCULOTROPIN; VASCULOTROPIN ANTIBODY;

EID: 84875336557     PISSN: 15748928     EISSN: None     Source Type: Journal    
DOI: 10.2174/1574892811308020003     Document Type: Review
Times cited : (31)

References (180)
  • 1
    • 78649237682 scopus 로고    scopus 로고
    • Women survive breast cancer but fall victim to heart failure: The shadows and lights of targeted therapy
    • Maurea N, Coppola C, Ragone G, Frasci G, Bonelli A, Romano C, et al. Women survive breast cancer but fall victim to heart failure: The shadows and lights of targeted therapy. J Cardiovasc Med (Hagerstown) 2010; 11(12): 861-8.
    • (2010) J Cardiovasc Med (Hagerstown) , vol.11 , Issue.12 , pp. 861-868
    • Maurea, N.1    Coppola, C.2    Ragone, G.3    Frasci, G.4    Bonelli, A.5    Romano, C.6
  • 2
    • 77954394371 scopus 로고    scopus 로고
    • A phase I/II study of neoadjuvant liposomal doxorubicin, paclitaxel, and hyperthermia in locally advanced breast cancer
    • Vujaskovic Z, Kim DW, Jones E, Lan L, McCall L, Dewhirst MW, et al. A phase I/II study of neoadjuvant liposomal doxorubicin, paclitaxel, and hyperthermia in locally advanced breast cancer. Int J Hyperthermia 2010; 26(5): 514-21.
    • (2010) Int J Hyperthermia , vol.26 , Issue.5 , pp. 514-521
    • Vujaskovic, Z.1    Kim, D.W.2    Jones, E.3    Lan, L.4    McCall, L.5    Dewhirst, M.W.6
  • 3
    • 38949174220 scopus 로고    scopus 로고
    • Capecitabine-related cardiotoxicity: Recognition and management
    • Saif MW, Tomita M, Ledbetter L, Diasio RB. Capecitabine-related cardiotoxicity: Recognition and management. J Support Oncol 2008; 6(1): 41-8.
    • (2008) J Support Oncol , vol.6 , Issue.1 , pp. 41-48
    • Saif, M.W.1    Tomita, M.2    Ledbetter, L.3    Diasio, R.B.4
  • 4
    • 62449193617 scopus 로고    scopus 로고
    • Docetaxel With cyclophosphamide is associated with an overall survival benefit compared with doxorubicin and cyclophosphamide: 7-Year follow-up of us oncology research trial 9735
    • Jones S, Holmes FA, O'Shaughnessy J, Blum JL, Vukelja SJ, McIntyre KJ, et al. Docetaxel With cyclophosphamide is associated with an overall survival benefit compared with doxorubicin and cyclophosphamide: 7-Year follow-up of us oncology research trial 9735. J Clin Oncol 2009; 27(8): 1177-83.
    • (2009) J Clin Oncol , vol.27 , Issue.8 , pp. 1177-1183
    • Jones, S.1    Holmes, F.A.2    O'Shaughnessy, J.3    Blum, J.L.4    Vukelja, S.J.5    McIntyre, K.J.6
  • 5
    • 84856223809 scopus 로고    scopus 로고
    • Dual HER2-targeted approaches in HER2-positive breast cancer
    • Ahn ER, Vogel CL. Dual HER2-targeted approaches in HER2-positive breast cancer. Breast Cancer Res Treat 2012; 131(2): 371-83.
    • (2012) Breast Cancer Res Treat , vol.131 , Issue.2 , pp. 371-383
    • Ahn, E.R.1    Vogel, C.L.2
  • 7
    • 77950142741 scopus 로고    scopus 로고
    • Nanoparticle-mediated cytoplasmic delivery of proteins to target cellular machinery
    • Bale SS, Kwon SJ, Shah DA, Banerjee A, Dordick JS, Kane RS. Nanoparticle-mediated cytoplasmic delivery of proteins to target cellular machinery. ACS Nano 2010; 4(3): 1493-500.
    • (2010) ACS Nano , vol.4 , Issue.3 , pp. 1493-1500
    • Bale, S.S.1    Kwon, S.J.2    Shah, D.A.3    Banerjee, A.4    Dordick, J.S.5    Kane, R.S.6
  • 8
    • 77956292811 scopus 로고    scopus 로고
    • The role of HER2 in cancer therapy and targeted drug delivery
    • Tai W, Mahato R, Cheng K. The role of HER2 in cancer therapy and targeted drug delivery. J Control Release 2010; 146(3): 264-75.
    • (2010) J Control Release , vol.146 , Issue.3 , pp. 264-275
    • Tai, W.1    Mahato, R.2    Cheng, K.3
  • 9
    • 0035874981 scopus 로고    scopus 로고
    • Trastuzumab (herceptin), a humanized anti-HER2 receptor monoclonal antibody, inhibits basal and activated HER2 ectodomain cleavage in breast cancer cells
    • Molina MA, Codony-Servat J, Albanell J, Rojo F, Arribas J, Baselga J. Trastuzumab (herceptin), a humanized anti-HER2 receptor monoclonal antibody, inhibits basal and activated HER2 ectodomain cleavage in breast cancer cells. Cancer Res 2001; 61(12): 4744-9.
    • (2001) Cancer Res , vol.61 , Issue.12 , pp. 4744-4749
    • Molina, M.A.1    Codony-Servat, J.2    Albanell, J.3    Rojo, F.4    Arribas, J.5    Baselga, J.6
  • 10
    • 34249317254 scopus 로고    scopus 로고
    • HER-2 overexpression increases the metastatic outgrowth of breast cancer cells in the brain
    • Palmieri D, Bronder JL, Herring JM, Yoneda T, Weil RJ, Stark AM, et al. HER-2 overexpression increases the metastatic outgrowth of breast cancer cells in the brain. Cancer Res 2007; 67(9): 4190-8.
    • (2007) Cancer Res , vol.67 , Issue.9 , pp. 4190-4198
    • Palmieri, D.1    Bronder, J.L.2    Herring, J.M.3    Yoneda, T.4    Weil, R.J.5    Stark, A.M.6
  • 11
    • 75449089516 scopus 로고    scopus 로고
    • Beyond trastuzumab: Small molecule tyrosine kinase inhibitors in HER-2-positive breast cancer
    • Roy V, Perez EA. Beyond trastuzumab: small molecule tyrosine kinase inhibitors in HER-2-positive breast cancer. Oncologist 2009; 14(11): 1061-9.
    • (2009) Oncologist , vol.14 , Issue.11 , pp. 1061-1069
    • Roy, V.1    Perez, E.A.2
  • 12
    • 79952631264 scopus 로고    scopus 로고
    • Rational use of trastuzumab in metastatic and locally advanced breast cancer: Implications of recent research
    • Goel S, Chirgwin J, Francis P, Stuart-Harris R, Dewar J, Mileshkin L, et al. Rational use of trastuzumab in metastatic and locally advanced breast cancer: Implications of recent research. Breast 2011; 20(2): 101-10.
    • (2011) Breast , vol.20 , Issue.2 , pp. 101-110
    • Goel, S.1    Chirgwin, J.2    Francis, P.3    Stuart-Harris, R.4    Dewar, J.5    Mileshkin, L.6
  • 13
    • 0036498781 scopus 로고    scopus 로고
    • Cardiac dysfunction in the trastuzumab clinical trials experience
    • Seidman A, Hudis C, Pierri MK, Shak S, Paton V, Ashby M, et al. Cardiac dysfunction in the trastuzumab clinical trials experience. J Clin Oncol 2002; 20(5): 1215-21.
    • (2002) J Clin Oncol , vol.20 , Issue.5 , pp. 1215-1221
    • Seidman, A.1    Hudis, C.2    Pierri, M.K.3    Shak, S.4    Paton, V.5    Ashby, M.6
  • 14
    • 77951058617 scopus 로고    scopus 로고
    • Trastuzumab-based therapy for patients with HER2-positive breast cancer: From early scientific development to foundation of care
    • Brufsky A. Trastuzumab-based therapy for patients with HER2-positive breast cancer: From early scientific development to foundation of care. Am J Clin Oncol 2010; 33(2): 186-95.
    • (2010) Am J Clin Oncol , vol.33 , Issue.2 , pp. 186-195
    • Brufsky, A.1
  • 15
    • 84864619911 scopus 로고    scopus 로고
    • Anti-HER2 single-chain antibody mediated DNMTs-siRNA delivery for targeted breast cancer therapy
    • Dou S, Yao YD, Yang XZ, Sun TM, Mao CQ, Song EW, et al. Anti-HER2 single-chain antibody mediated DNMTs-siRNA delivery for targeted breast cancer therapy. J Control Release 2012; 161(3): 875-83.
    • (2012) J Control Release , vol.161 , Issue.3 , pp. 875-883
    • Dou, S.1    Yao, Y.D.2    Yang, X.Z.3    Sun, T.M.4    Mao, C.Q.5    Song, E.W.6
  • 18
    • 0035874887 scopus 로고    scopus 로고
    • High affinity restricts the localization and tumor penetration of single-chain fv antibody molecules
    • Adams GP, Schier R, McCall AM, Simmons HH, Horak EM, Alpaugh RK, et al. High affinity restricts the localization and tumor penetration of single-chain fv antibody molecules. Cancer Res 2001; 61(12): 4750-5.
    • (2001) Cancer Res , vol.61 , Issue.12 , pp. 4750-4755
    • Adams, G.P.1    Schier, R.2    McCall, A.M.3    Simmons, H.H.4    Horak, E.M.5    Alpaugh, R.K.6
  • 20
    • 72649087326 scopus 로고    scopus 로고
    • Estrogen action: A historic perspective on the implications of considering alternative approaches
    • Jensen EV, Jacobson HI, Walf AA, Frye CA. Estrogen action: A historic perspective on the implications of considering alternative approaches. Physiol Behav 2010; 99(2): 151-62.
    • (2010) Physiol Behav , vol.99 , Issue.2 , pp. 151-162
    • Jensen, E.V.1    Jacobson, H.I.2    Walf, A.A.3    Frye, C.A.4
  • 23
    • 76749091057 scopus 로고    scopus 로고
    • Activity of fulvestrant 500 mg versus anastrozole 1 mg as first-line treatment for advanced breast cancer: Results from the FIRST study
    • Robertson JF, Llombart-Cussac A, Rolski J, Feltl D, Dewar J, Macpherson E, et al. Activity of fulvestrant 500 mg versus anastrozole 1 mg as first-line treatment for advanced breast cancer: results from the FIRST study. J Clin Oncol 2009; 27(27): 4530-5.
    • (2009) J Clin Oncol , vol.27 , Issue.27 , pp. 4530-4535
    • Robertson, J.F.1    Llombart-Cussac, A.2    Rolski, J.3    Feltl, D.4    Dewar, J.5    McPherson, E.6
  • 28
    • 84863617400 scopus 로고    scopus 로고
    • Promising therapeutic options in triple-negative breast cancer
    • Bilici A, Arslan C, Altundag K. Promising therapeutic options in triple-negative breast cancer. J Buon 2012; 17(2): 209-22.
    • (2012) J Buon , vol.17 , Issue.2 , pp. 209-222
    • Bilici, A.1    Arslan, C.2    Altundag, K.3
  • 29
    • 74049105681 scopus 로고    scopus 로고
    • WNT signaling enhances breast cancer cell motility and blockade of the WNT pathway by sFRP1 suppresses MDA-MB-231 xenograft growth
    • Matsuda Y, Schlange T, Oakeley EJ, Boulay A, Hynes NE. WNT signaling enhances breast cancer cell motility and blockade of the WNT pathway by sFRP1 suppresses MDA-MB-231 xenograft growth. Breast Cancer Res 2009; 11(3): R32.
    • (2009) Breast Cancer Res , vol.11 , Issue.3
    • Matsuda, Y.1    Schlange, T.2    Oakeley, E.J.3    Boulay, A.4    Hynes, N.E.5
  • 30
    • 70349332814 scopus 로고    scopus 로고
    • Current data of targeted therapies for the treatment of triple-negative advanced breast cancer: Empiricism or evidence-based?
    • Petrelli F, Cabiddu M, Ghilardi M, Barni S. Current data of targeted therapies for the treatment of triple-negative advanced breast cancer: Empiricism or evidence-based? Expert Opin Investig Drugs 2009; 18(10): 1467-77.
    • (2009) Expert Opin Investig Drugs , vol.18 , Issue.10 , pp. 1467-1477
    • Petrelli, F.1    Cabiddu, M.2    Ghilardi, M.3    Barni, S.4
  • 31
    • 84892572211 scopus 로고    scopus 로고
    • Efficacy and safety of docetaxel combined with oxaliplatin as a neoadjuvant chemotherapy regimen for Chinese triple-negative local advanced breast cancer patients: A prospective, open, and unicentric phase II clinical trial
    • [Epub ahead of print]
    • Fei F, Chen C, Xue J, Di GH, Lu JS, Liu GY, et al. Efficacy and safety of docetaxel combined with oxaliplatin as a neoadjuvant chemotherapy regimen for Chinese triple-negative local advanced breast cancer patients: A prospective, open, and unicentric phase II clinical trial. Am J Clin Oncol 2012. [Epub ahead of print].
    • (2012) Am J Clin Oncol
    • Fei, F.1    Chen, C.2    Xue, J.3    Di, G.H.4    Lu, J.S.5    Liu, G.Y.6
  • 32
    • 79952261244 scopus 로고    scopus 로고
    • EGFR-homing dsRNA activates cancer-targeted immune response and eliminates disseminated EGFR-overexpressing tumors in mice
    • Shir A, Ogris M, Roedl W, Wagner E, Levitzki A. EGFR-homing dsRNA activates cancer-targeted immune response and eliminates disseminated EGFR-overexpressing tumors in mice. Clin Cancer Res 2011; 17(5): 1033-43.
    • (2011) Clin Cancer Res , vol.17 , Issue.5 , pp. 1033-1043
    • Shir, A.1    Ogris, M.2    Roedl, W.3    Wagner, E.4    Levitzki, A.5
  • 36
    • 79952785519 scopus 로고    scopus 로고
    • Multiple cancer/testis antigens are preferentially expressed in hormone-receptor negative and high-grade breast cancers
    • Chen YT, Ross DS, Chiu R, Zhou XK, Chen YY, Lee P, et al. Multiple cancer/testis antigens are preferentially expressed in hormone-receptor negative and high-grade breast cancers. PLoS One 2011; 6(3): e17876.
    • (2011) PLoS One , vol.6 , Issue.3
    • Chen, Y.T.1    Ross, D.S.2    Chiu, R.3    Zhou, X.K.4    Chen, Y.Y.5    Lee, P.6
  • 38
    • 84858703841 scopus 로고    scopus 로고
    • The miR-200 and miR-221/222 microRNA families: Opposing effects on epithelial identity
    • Howe EN, Cochrane DR, Richer JK. The miR-200 and miR-221/222 microRNA families: Opposing effects on epithelial identity. J Mammary Gland Biol Neoplasia 2012; 17(1): 65-77.
    • (2012) J Mammary Gland Biol Neoplasia , vol.17 , Issue.1 , pp. 65-77
    • Howe, E.N.1    Cochrane, D.R.2    Richer, J.K.3
  • 42
    • 84866269413 scopus 로고    scopus 로고
    • Triple negative breast cancer: A brief review of its characteristics and treatment options
    • Griffiths CL, Olin JL. Triple negative breast cancer: A brief review of its characteristics and treatment options. J Pharm Pract 2012; 25(3): 319-23.
    • (2012) J Pharm Pract , vol.25 , Issue.3 , pp. 319-323
    • Griffiths, C.L.1    Olin, J.L.2
  • 43
    • 84858975438 scopus 로고    scopus 로고
    • Poly (ADP-ribose) polymerase (PARP): Rationale, preclinical and clinical evidences of its inhibition as breast cancer treatment
    • Orlando L, Schiavone P, Fedele P, Calvani N, Nacci A, Cinefra M, et al. Poly (ADP-ribose) polymerase (PARP): Rationale, preclinical and clinical evidences of its inhibition as breast cancer treatment. Expert Opin Ther Targets 2012; 16 (Suppl 2): S83-9.
    • (2012) Expert Opin Ther Targets , vol.16 , Issue.SUPPL. 2
    • Orlando, L.1    Schiavone, P.2    Fedele, P.3    Calvani, N.4    Nacci, A.5    Cinefra, M.6
  • 45
    • 84856889082 scopus 로고    scopus 로고
    • The potential for poly (ADP-ribose) polymerase inhibitors in cancer therapy
    • Javle M, Curtin NJ. The potential for poly (ADP-ribose) polymerase inhibitors in cancer therapy. Ther Adv Med Oncol 2011; 3(6): 257-67.
    • (2011) Ther Adv Med Oncol , vol.3 , Issue.6 , pp. 257-267
    • Javle, M.1    Curtin, N.J.2
  • 46
    • 83355172188 scopus 로고    scopus 로고
    • PAX2 is activated by estradiol in breast cancer cells of the luminal subgroup selectively, to confer a low invasive phenotype
    • Beauchemin D, Lacombe C, Van Themsche C. PAX2 is activated by estradiol in breast cancer cells of the luminal subgroup selectively, to confer a low invasive phenotype. Mol Cancer 2011; 10: 148.
    • (2011) Mol Cancer , vol.10 , pp. 148
    • Beauchemin, D.1    Lacombe, C.2    van Themsche, C.3
  • 47
    • 34848838572 scopus 로고    scopus 로고
    • Functional analysis of the host defense peptide Human Beta Defensin-1: New insight into its potential role in cancer
    • Bullard RS, Gibson W, Bose SK, Belgrave JK, Eaddy AC, Wright CJ, et al. Functional analysis of the host defense peptide Human Beta Defensin-1: New insight into its potential role in cancer. Mol Immunol 2008; 45(3): 839-48.
    • (2008) Mol Immunol , vol.45 , Issue.3 , pp. 839-848
    • Bullard, R.S.1    Gibson, W.2    Bose, S.K.3    Belgrave, J.K.4    Eaddy, A.C.5    Wright, C.J.6
  • 48
    • 60949110142 scopus 로고    scopus 로고
    • PAX2 oncogene negatively regulates the expression of the host defense peptide human beta defensin-1 in prostate cancer
    • Bose SK, Gibson W, Bullard RS, Donald CD. PAX2 oncogene negatively regulates the expression of the host defense peptide human beta defensin-1 in prostate cancer. Mol Immunol 2009; 46(6): 1140-8.
    • (2009) Mol Immunol , vol.46 , Issue.6 , pp. 1140-1148
    • Bose, S.K.1    Gibson, W.2    Bullard, R.S.3    Donald, C.D.4
  • 60
    • 0242468884 scopus 로고    scopus 로고
    • A phase I/II dose-escalation trial of bevacizumab in previously treated metastatic breast cancer
    • Cobleigh MA, Langmuir VK, Sledge GW, Miller KD, Haney L, Novotny WF, et al. A phase I/II dose-escalation trial of bevacizumab in previously treated metastatic breast cancer. Semin Oncol 2003; 30(5 Suppl 16): 117-24.
    • (2003) Semin Oncol , vol.30 , Issue.5 SUPPL. 16 , pp. 117-124
    • Cobleigh, M.A.1    Langmuir, V.K.2    Sledge, G.W.3    Miller, K.D.4    Haney, L.5    Novotny, W.F.6
  • 61
    • 0026485002 scopus 로고
    • Vascular endothelial growth factor induced by hypoxia may mediate hypoxia-initiated angiogenesis
    • Shweiki D, Itin A, Soffer D, Keshet E. Vascular endothelial growth factor induced by hypoxia may mediate hypoxia-initiated angiogenesis. Nature 1992; 359(6398): 843-5.
    • (1992) Nature , vol.359 , Issue.6398 , pp. 843-845
    • Shweiki, D.1    Itin, A.2    Soffer, D.3    Keshet, E.4
  • 62
    • 34547124062 scopus 로고    scopus 로고
    • Hypoxia: A key regulator of angiogenesis in cancer
    • Liao D, Johnson RS. Hypoxia: A key regulator of angiogenesis in cancer. Cancer Metastasis Rev 2007; 26(2): 281-90.
    • (2007) Cancer Metastasis Rev , vol.26 , Issue.2 , pp. 281-290
    • Liao, D.1    Johnson, R.S.2
  • 63
    • 70350002279 scopus 로고    scopus 로고
    • Adverse effects of anticancer agents that target the VEGF pathway
    • Chen HX, Cleck JN. Adverse effects of anticancer agents that target the VEGF pathway. Nat Rev Clin Oncol 2009; 6(8): 465-77.
    • (2009) Nat Rev Clin Oncol , vol.6 , Issue.8 , pp. 465-477
    • Chen, H.X.1    Cleck, J.N.2
  • 64
    • 77954668887 scopus 로고    scopus 로고
    • Angiogenesis inhibitors: Current strategies and future prospects
    • Cook KM, Figg WD. Angiogenesis inhibitors: Current strategies and future prospects. CA Cancer J Clin 2010; 60(4): 222-43.
    • (2010) CA Cancer J Clin , vol.60 , Issue.4 , pp. 222-243
    • Cook, K.M.1    Figg, W.D.2
  • 65
    • 84869465976 scopus 로고    scopus 로고
    • North Central Cancer Treatment Group (NCCTG) N0537: Phase II trial of VEGF-Trap in patients with metastatic breast cancer previously treated with an anthracycline and/or a taxane
    • Sideras K, Dueck AC, Hobday TJ, Rowland KM, Jr., Allred JB, Northfelt DW, et al. North Central Cancer Treatment Group (NCCTG) N0537: Phase II trial of VEGF-Trap in patients with metastatic breast cancer previously treated with an anthracycline and/or a taxane. Clin Breast Cancer 2012; 12(6): 387-91.
    • (2012) Clin Breast Cancer , vol.12 , Issue.6 , pp. 387-391
    • Sideras, K.1    Dueck, A.C.2    Hobday, T.J.3    Rowland Jr., K.M.4    Allred, J.B.5    Northfelt, D.W.6
  • 70
    • 77952399799 scopus 로고    scopus 로고
    • Phase II study on the addition of ASA404 (vadimezan; 5,6-dimethylxanthenone-4-acetic acid) to docetaxel in CRMPC
    • Pili R, Rosenthal MA, Mainwaring PN, Van Hazel G, Srinivas S, Dreicer R, et al. Phase II study on the addition of ASA404 (vadimezan; 5,6-dimethylxanthenone-4-acetic acid) to docetaxel in CRMPC. Clin Cancer Res 2010; 16(10): 2906-14.
    • (2010) Clin Cancer Res , vol.16 , Issue.10 , pp. 2906-2914
    • Pili, R.1    Rosenthal, M.A.2    Mainwaring, P.N.3    van Hazel, G.4    Srinivas, S.5    Dreicer, R.6
  • 75
    • 33750812269 scopus 로고    scopus 로고
    • Angiogenesis-associated protein annexin II in breast cancer: Selective expression in invasive breast cancer and contribution to tumor invasion and progression
    • Sharma MR, Koltowski L, Ownbey RT, Tuszynski GP, Sharma MC. Angiogenesis-associated protein annexin II in breast cancer: Selective expression in invasive breast cancer and contribution to tumor invasion and progression. Exp Mol Pathol 2006; 81(2): 146-56.
    • (2006) Exp Mol Pathol , vol.81 , Issue.2 , pp. 146-156
    • Sharma, M.R.1    Koltowski, L.2    Ownbey, R.T.3    Tuszynski, G.P.4    Sharma, M.C.5
  • 76
    • 0029670206 scopus 로고    scopus 로고
    • p16INK4A as a human tumor suppressor
    • Shapiro GI, Rollins BJ. p16INK4A as a human tumor suppressor. Biochim Biophys Acta 1996; 1242(3): 165-9.
    • (1996) Biochim Biophys Acta , vol.1242 , Issue.3 , pp. 165-169
    • Shapiro, G.I.1    Rollins, B.J.2
  • 77
    • 84875333898 scopus 로고    scopus 로고
    • Inhibition of breast tumor cell growth by ectopic expression of p16/INK4A via combined effects of cell cycle arrest, senescence and apoptotic induction, and angiogenesis inhibition
    • Lu Y, Zhang X, Zhang J. Inhibition of breast tumor cell growth by ectopic expression of p16/INK4A via combined effects of cell cycle arrest, senescence and apoptotic induction, and angiogenesis inhibition. J Cancer 2012; 3: 333-44.
    • (2012) J Cancer , vol.3 , pp. 333-344
    • Lu, Y.1    Zhang, X.2    Zhang, J.3
  • 78
    • 84868195812 scopus 로고    scopus 로고
    • Ellagic acid, a phenolic compound, exerts anti-angiogenesis effects via VEGFR-2 signaling pathway in breast cancer
    • Wang N, Wang ZY, Mo SL, Loo TY, Wang DM, Luo HB, et al. Ellagic acid, a phenolic compound, exerts anti-angiogenesis effects via VEGFR-2 signaling pathway in breast cancer. Breast Cancer Res Treat 2012; 134(3): 943-55.
    • (2012) Breast Cancer Res Treat , vol.134 , Issue.3 , pp. 943-955
    • Wang, N.1    Wang, Z.Y.2    Mo, S.L.3    Loo, T.Y.4    Wang, D.M.5    Luo, H.B.6
  • 79
    • 84867771909 scopus 로고    scopus 로고
    • CCL2/CCR2 Chemokine signaling coordinates survival and motility of breast cancer cells through Smad3 protein-and p42/44 Mitogen-activated Protein Kinase (MAPK)-dependent mechanisms
    • Fang WB, Jokar I, Zou A, Lambert D, Dendukuri P, Cheng N. CCL2/CCR2 Chemokine signaling coordinates survival and motility of breast cancer cells through Smad3 protein-and p42/44 Mitogen-activated Protein Kinase (MAPK)-dependent mechanisms. J Biol Chem 2012; 287(43): 36593-608.
    • (2012) J Biol Chem , vol.287 , Issue.43 , pp. 36593-36608
    • Fang, W.B.1    Jokar, I.2    Zou, A.3    Lambert, D.4    Dendukuri, P.5    Cheng, N.6
  • 80
    • 84867563621 scopus 로고    scopus 로고
    • Importance of chemokine (CC-motif) ligand 2 in breast cancer
    • Steiner JL, Murphy EA. Importance of chemokine (CC-motif) ligand 2 in breast cancer. Int J Biol Markers 2012; 27(3): e179-85.
    • (2012) Int J Biol Markers , vol.27 , Issue.3
    • Steiner, J.L.1    Murphy, E.A.2
  • 81
    • 84863724938 scopus 로고    scopus 로고
    • Targeting monocyte chemotactic protein-1 synthesis with bindarit induces tumor regression in prostate and breast cancer animal models
    • Zollo M, Di Dato V, Spano D, De Martino D, Liguori L, Marino N, et al. Targeting monocyte chemotactic protein-1 synthesis with bindarit induces tumor regression in prostate and breast cancer animal models. Clin Exp Metastasis 2012; 29(6): 585-601.
    • (2012) Clin Exp Metastasis , vol.29 , Issue.6 , pp. 585-601
    • Zollo, M.1    Di Dato, V.2    Spano, D.3    de Martino, D.4    Liguori, L.5    Marino, N.6
  • 82
    • 84859715721 scopus 로고    scopus 로고
    • Tumor microenvironment: A main actor in the metastasis process
    • Spano D, Zollo M. Tumor microenvironment: A main actor in the metastasis process. Clin Exp Metastasis 2012; 29(4): 381-95.
    • (2012) Clin Exp Metastasis , vol.29 , Issue.4 , pp. 381-395
    • Spano, D.1    Zollo, M.2
  • 85
    • 0034800309 scopus 로고    scopus 로고
    • Heterogeneity of proteinkinase C activity and PKCzeta expression in clinical breast carcinomas
    • Schondorf T, Kurbacher CM, Becker M, Warm M, Kolhagen H, Gohring UJ. Heterogeneity of proteinkinase C activity and PKCzeta expression in clinical breast carcinomas. Clin Exp Med 2001; 1(1): 1-8.
    • (2001) Clin Exp Med , vol.1 , Issue.1 , pp. 1-8
    • Schondorf, T.1    Kurbacher, C.M.2    Becker, M.3    Warm, M.4    Kolhagen, H.5    Gohring, U.J.6
  • 87
    • 36749015683 scopus 로고    scopus 로고
    • Cannabidiol as a novel inhibitor of Id-1 gene expression in aggressive breast cancer cells
    • McAllister SD, Christian RT, Horowitz MP, Garcia A, Desprez PY. Cannabidiol as a novel inhibitor of Id-1 gene expression in aggressive breast cancer cells. Mol Cancer Ther 2007; 6(11): 2921-7.
    • (2007) Mol Cancer Ther , vol.6 , Issue.11 , pp. 2921-2927
    • McAllister, S.D.1    Christian, R.T.2    Horowitz, M.P.3    Garcia, A.4    Desprez, P.Y.5
  • 89
    • 84859409756 scopus 로고    scopus 로고
    • Antitumor activity of a novel bispecific antibody that targets the ErbB2/ErbB3 oncogenic unit and inhibits heregulininduced activation of ErbB3
    • McDonagh CF, Huhalov A, Harms BD, Adams S, Paragas V, Oyama S, et al. Antitumor activity of a novel bispecific antibody that targets the ErbB2/ErbB3 oncogenic unit and inhibits heregulininduced activation of ErbB3. Mol Cancer Ther 2012; 11(3): 582-93.
    • (2012) Mol Cancer Ther , vol.11 , Issue.3 , pp. 582-593
    • McDonagh, C.F.1    Huhalov, A.2    Harms, B.D.3    Adams, S.4    Paragas, V.5    Oyama, S.6
  • 91
    • 84859985179 scopus 로고    scopus 로고
    • The multifactorial role of leptin in driving the breast cancer microenvironment
    • Ando S, Catalano S. The multifactorial role of leptin in driving the breast cancer microenvironment. Nat Rev Endocrinol 2012; 8(5): 263-75.
    • (2012) Nat Rev Endocrinol , vol.8 , Issue.5 , pp. 263-275
    • Ando, S.1    Catalano, S.2
  • 96
    • 77949566512 scopus 로고    scopus 로고
    • Leptin as a potential therapeutic target for breast cancer prevention and treatment
    • Ray A, Cleary MP. Leptin as a potential therapeutic target for breast cancer prevention and treatment. Expert Opin Ther Targets 2010; 14(4): 443-51.
    • (2010) Expert Opin Ther Targets , vol.14 , Issue.4 , pp. 443-451
    • Ray, A.1    Cleary, M.P.2
  • 97
    • 34248157798 scopus 로고    scopus 로고
    • Obesity hormone leptin: A new target in breast cancer?
    • Surmacz E. Obesity hormone leptin: A new target in breast cancer? Breast Cancer Res 2007; 9(1): 301.
    • (2007) Breast Cancer Res , vol.9 , Issue.1 , pp. 301
    • Surmacz, E.1
  • 102
    • 77951444290 scopus 로고    scopus 로고
    • Time-dependent migration of systemically delivered bone marrow mesenchymal stem cells to the infarcted heart
    • Assis AC, Carvalho JL, Jacoby BA, Ferreira RL, Castanheira P, Diniz SO, et al. Time-dependent migration of systemically delivered bone marrow mesenchymal stem cells to the infarcted heart. Cell Transplant 2010; 19(2): 219-30.
    • (2010) Cell Transplant , vol.19 , Issue.2 , pp. 219-230
    • Assis, A.C.1    Carvalho, J.L.2    Jacoby, B.A.3    Ferreira, R.L.4    Castanheira, P.5    Diniz, S.O.6
  • 103
    • 34547763362 scopus 로고    scopus 로고
    • Exogenous mesenchymal stem cells localize to the kidney by means of CD44 following acute tubular injury
    • Herrera MB, Bussolati B, Bruno S, Morando L, Mauriello-Romanazzi G, Sanavio F, et al. Exogenous mesenchymal stem cells localize to the kidney by means of CD44 following acute tubular injury. Kidney Int 2007; 72(4): 430-41.
    • (2007) Kidney Int , vol.72 , Issue.4 , pp. 430-441
    • Herrera, M.B.1    Bussolati, B.2    Bruno, S.3    Morando, L.4    Mauriello-Romanazzi, G.5    Sanavio, F.6
  • 104
    • 33751252831 scopus 로고    scopus 로고
    • Adult bone-marrowderived mesenchymal stem cells contribute to wound healing of skin appendages
    • Li H, Fu X, Ouyang Y, Cai C, Wang J, Sun T. Adult bone-marrowderived mesenchymal stem cells contribute to wound healing of skin appendages. Cell Tissue Res 2006; 326(3): 725-36.
    • (2006) Cell Tissue Res , vol.326 , Issue.3 , pp. 725-736
    • Li, H.1    Fu, X.2    Ouyang, Y.3    Cai, C.4    Wang, J.5    Sun, T.6
  • 105
    • 77952805220 scopus 로고    scopus 로고
    • Human mesenchymal stem cells and their use in cell-based therapies
    • Motaln H, Schichor C, Lah TT. Human mesenchymal stem cells and their use in cell-based therapies. Cancer 2010; 116(11): 2519-30.
    • (2010) Cancer , vol.116 , Issue.11 , pp. 2519-2530
    • Motaln, H.1    Schichor, C.2    Lah, T.T.3
  • 106
    • 77951753751 scopus 로고    scopus 로고
    • Chemokines mediate mesenchymal stem cell migration toward gliomas in vitro
    • Xu F, Shi J, Yu B, Ni W, Wu X, Gu Z. Chemokines mediate mesenchymal stem cell migration toward gliomas in vitro. Oncol Rep 2010; 23(6): 1561-7.
    • (2010) Oncol Rep , vol.23 , Issue.6 , pp. 1561-1567
    • Xu, F.1    Shi, J.2    Yu, B.3    Ni, W.4    Wu, X.5    Gu, Z.6
  • 107
    • 66249083525 scopus 로고    scopus 로고
    • Mesenchymal stem cell delivery of TRAIL can eliminate metastatic cancer
    • Loebinger MR, Eddaoudi A, Davies D, Janes SM. Mesenchymal stem cell delivery of TRAIL can eliminate metastatic cancer. Cancer Res 2009; 69(10): 4134-42.
    • (2009) Cancer Res , vol.69 , Issue.10 , pp. 4134-4142
    • Loebinger, M.R.1    Eddaoudi, A.2    Davies, D.3    Janes, S.M.4
  • 108
    • 71549114206 scopus 로고    scopus 로고
    • Magnetic resonance imaging of mesenchymal stem cells homing to pulmonary metastases using biocompatible magnetic nanoparticles
    • Loebinger MR, Kyrtatos PG, Turmaine M, Price AN, Pankhurst Q, Lythgoe MF, et al. Magnetic resonance imaging of mesenchymal stem cells homing to pulmonary metastases using biocompatible magnetic nanoparticles. Cancer Res 2009; 69(23): 8862-7.
    • (2009) Cancer Res , vol.69 , Issue.23 , pp. 8862-8867
    • Loebinger, M.R.1    Kyrtatos, P.G.2    Turmaine, M.3    Price, A.N.4    Pankhurst, Q.5    Lythgoe, M.F.6
  • 109
    • 43049139914 scopus 로고    scopus 로고
    • Inflammation and tumor microenvironments: Defining the migratory itinerary of mesenchymal stem cells
    • Spaeth E, Klopp A, Dembinski J, Andreeff M, Marini F. Inflammation and tumor microenvironments: Defining the migratory itinerary of mesenchymal stem cells. Gene Ther 2008; 15(10): 730-8.
    • (2008) Gene Ther , vol.15 , Issue.10 , pp. 730-738
    • Spaeth, E.1    Klopp, A.2    Dembinski, J.3    Andreeff, M.4    Marini, F.5
  • 110
    • 41149159755 scopus 로고    scopus 로고
    • A tumorselective biotherapy with prolonged impact on established metastases based on cytokine gene-engineered MSCs
    • Chen X, Lin X, Zhao J, Shi W, Zhang H, Wang Y, et al. A tumorselective biotherapy with prolonged impact on established metastases based on cytokine gene-engineered MSCs. Mol Ther 2008; 16(4): 749-56.
    • (2008) Mol Ther , vol.16 , Issue.4 , pp. 749-756
    • Chen, X.1    Lin, X.2    Zhao, J.3    Shi, W.4    Zhang, H.5    Wang, Y.6
  • 111
    • 37549036588 scopus 로고    scopus 로고
    • Tumor irradiation increases the recruitment of circulating mesenchymal stem cells into the tumor microenvironment
    • Klopp AH, Spaeth EL, Dembinski JL, Woodward WA, Munshi A, Meyn RE, et al. Tumor irradiation increases the recruitment of circulating mesenchymal stem cells into the tumor microenvironment. Cancer Res 2007; 67(24): 11687-95.
    • (2007) Cancer Res , vol.67 , Issue.24 , pp. 11687-11695
    • Klopp, A.H.1    Spaeth, E.L.2    Dembinski, J.L.3    Woodward, W.A.4    Munshi, A.5    Meyn, R.E.6
  • 112
    • 70349515175 scopus 로고    scopus 로고
    • Radiation increases invasion of gene-modified mesenchymal stem cells into tumors
    • Zielske SP, Livant DL, Lawrence TS. Radiation increases invasion of gene-modified mesenchymal stem cells into tumors. Int J Radiat Oncol Biol Phys 2009; 75(3): 843-53.
    • (2009) Int J Radiat Oncol Biol Phys , vol.75 , Issue.3 , pp. 843-853
    • Zielske, S.P.1    Livant, D.L.2    Lawrence, T.S.3
  • 113
    • 84867680330 scopus 로고    scopus 로고
    • Stem cell implants for cancer therapy: TRAILexpressing mesenchymal stem cells target cancer cells in situ
    • Reagan MR, Seib FP, McMillin DW, Sage EK, Mitsiades CS, Janes SM, et al. Stem cell implants for cancer therapy: TRAILexpressing mesenchymal stem cells target cancer cells in situ. J Breast Cancer 2012; 15(3): 273-82.
    • (2012) J Breast Cancer , vol.15 , Issue.3 , pp. 273-282
    • Reagan, M.R.1    Seib, F.P.2    McMillin, D.W.3    Sage, E.K.4    Mitsiades, C.S.5    Janes, S.M.6
  • 114
    • 84860639631 scopus 로고    scopus 로고
    • Mesenchymal stem cells engineered for cancer therapy
    • Shah K. Mesenchymal stem cells engineered for cancer therapy. Adv Drug Deliv Rev 2012; 64(8): 739-48.
    • (2012) Adv Drug Deliv Rev , vol.64 , Issue.8 , pp. 739-748
    • Shah, K.1
  • 116
    • 84860513584 scopus 로고    scopus 로고
    • The bad and the good of mesenchymal stem cells in cancer: Boosters of tumor growth and vehicles for targeted delivery of anticancer agents
    • Galderisi U, Giordano A, Paggi MG. The bad and the good of mesenchymal stem cells in cancer: Boosters of tumor growth and vehicles for targeted delivery of anticancer agents. World J Stem Cells 2010; 2(1): 5-12.
    • (2010) World J Stem Cells , vol.2 , Issue.1 , pp. 5-12
    • Galderisi, U.1    Giordano, A.2    Paggi, M.G.3
  • 117
    • 43049088843 scopus 로고    scopus 로고
    • Stem and progenitor cellmediated tumor selective gene therapy
    • Aboody KS, Najbauer J, Danks MK. Stem and progenitor cellmediated tumor selective gene therapy. Gene Ther 2008; 15(10): 739-52.
    • (2008) Gene Ther , vol.15 , Issue.10 , pp. 739-752
    • Aboody, K.S.1    Najbauer, J.2    Danks, M.K.3
  • 119
    • 77949514437 scopus 로고    scopus 로고
    • Neural stem cells as a novel platform for tumorspecific delivery of therapeutic antibodies
    • Frank RT, Edmiston M, Kendall SE, Najbauer J, Cheung CW, Kassa T, et al. Neural stem cells as a novel platform for tumorspecific delivery of therapeutic antibodies. PLoS One 2009; 4(12): e8314.
    • (2009) PLoS One , vol.4 , Issue.12
    • Frank, R.T.1    Edmiston, M.2    Kendall, S.E.3    Najbauer, J.4    Cheung, C.W.5    Kassa, T.6
  • 120
    • 61649103519 scopus 로고    scopus 로고
    • Human neural stem cells can target and deliver therapeutic genes to breast cancer brain metastases
    • Joo KM, Park IH, Shin JY, Jin J, Kang BG, Kim MH, et al. Human neural stem cells can target and deliver therapeutic genes to breast cancer brain metastases. Mol Ther 2009; 17(3): 570-5.
    • (2009) Mol Ther , vol.17 , Issue.3 , pp. 570-575
    • Joo, K.M.1    Park, I.H.2    Shin, J.Y.3    Jin, J.4    Kang, B.G.5    Kim, M.H.6
  • 122
    • 33846227546 scopus 로고    scopus 로고
    • Getting the right stuff: Controlling neural stem cell state and fate in vivo and in vitro with biomaterials
    • Teixeira AI, Duckworth JK, Hermanson O. Getting the right stuff: Controlling neural stem cell state and fate in vivo and in vitro with biomaterials. Cell Res 2007; 17(1): 56-61.
    • (2007) Cell Res , vol.17 , Issue.1 , pp. 56-61
    • Teixeira, A.I.1    Duckworth, J.K.2    Hermanson, O.3
  • 123
    • 46949107691 scopus 로고    scopus 로고
    • Mechanisms of disease: The role of stem cells in the biology and treatment of gliomas
    • Dietrich J, Imitola J, Kesari S. Mechanisms of disease: The role of stem cells in the biology and treatment of gliomas. Nat Clin Pract Oncol 2008; 5(7): 393-404.
    • (2008) Nat Clin Pract Oncol , vol.5 , Issue.7 , pp. 393-404
    • Dietrich, J.1    Imitola, J.2    Kesari, S.3
  • 125
    • 80455162612 scopus 로고    scopus 로고
    • Proteolytically stable cancer targeting peptides with high affinity for breast cancer cells
    • Soudy R, Gill A, Sprules T, Lavasanifar A, Kaur K. Proteolytically stable cancer targeting peptides with high affinity for breast cancer cells. J Med Chem 2011; 54(21): 7523-34.
    • (2011) J Med Chem , vol.54 , Issue.21 , pp. 7523-7534
    • Soudy, R.1    Gill, A.2    Sprules, T.3    Lavasanifar, A.4    Kaur, K.5
  • 130
    • 58149240891 scopus 로고    scopus 로고
    • RNA aptamer blockade of osteopontin inhibits growth and metastasis of MDA-MB231 breast cancer cells
    • Mi Z, Guo H, Russell MB, Liu Y, Sullenger BA, Kuo PC. RNA aptamer blockade of osteopontin inhibits growth and metastasis of MDA-MB231 breast cancer cells. Mol Ther 2009; 17(1): 153-61.
    • (2009) Mol Ther , vol.17 , Issue.1 , pp. 153-161
    • Mi, Z.1    Guo, H.2    Russell, M.B.3    Liu, Y.4    Sullenger, B.A.5    Kuo, P.C.6
  • 131
    • 77958152852 scopus 로고    scopus 로고
    • Delivering cargoes into cancer cells using DNA aptamers targeting internalized surface portals
    • Orava EW, Cicmil N, Gariepy J. Delivering cargoes into cancer cells using DNA aptamers targeting internalized surface portals. Biochim Biophys Acta 2010; 1798(12): 2190-200.
    • (2010) Biochim Biophys Acta , vol.1798 , Issue.12 , pp. 2190-2200
    • Orava, E.W.1    Cicmil, N.2    Gariepy, J.3
  • 135
    • 0037133217 scopus 로고    scopus 로고
    • A peptide derived from alpha-fetoprotein prevents the growth of estrogen-dependent human breast cancers sensitive and resistant to tamoxifen
    • Bennett JA, Mesfin FB, Andersen TT, Gierthy JF, Jacobson HI. A peptide derived from alpha-fetoprotein prevents the growth of estrogen-dependent human breast cancers sensitive and resistant to tamoxifen. Proc Natl Acad Sci USA 2002; 99(4): 2211-5.
    • (2002) Proc Natl Acad Sci USA , vol.99 , Issue.4 , pp. 2211-2215
    • Bennett, J.A.1    Mesfin, F.B.2    Andersen, T.T.3    Gierthy, J.F.4    Jacobson, H.I.5
  • 139
    • 79961079796 scopus 로고    scopus 로고
    • Antiangiogenic antitumor activity of HPMA copolymerpaclitaxel-alendronate conjugate on breast cancer bone metastasis mouse model
    • Miller K, Eldar-Boock A, Polyak D, Segal E, Benayoun L, Shaked Y, et al. Antiangiogenic antitumor activity of HPMA copolymerpaclitaxel-alendronate conjugate on breast cancer bone metastasis mouse model. Mol Pharm 2011; 8(4): 1052-62.
    • (2011) Mol Pharm , vol.8 , Issue.4 , pp. 1052-1062
    • Miller, K.1    Eldar-Boock, A.2    Polyak, D.3    Segal, E.4    Benayoun, L.5    Shaked, Y.6
  • 140
    • 84865370343 scopus 로고    scopus 로고
    • Combination drug delivery approaches in metastatic breast cancer
    • Lee JH, Nan A. Combination drug delivery approaches in metastatic breast cancer. J Drug Deliv 2012; 2012: 915375.
    • (2012) J Drug Deliv , vol.2012 , pp. 915375
    • Lee, J.H.1    Nan, A.2
  • 143
    • 79951847458 scopus 로고    scopus 로고
    • Polymalic acid-based nanobiopolymer provides efficient systemic breast cancer treatment by inhibiting both HER2/neu receptor synthesis and activity
    • Inoue S, Ding H, Portilla-Arias J, Hu J, Konda B, Fujita M, et al. Polymalic acid-based nanobiopolymer provides efficient systemic breast cancer treatment by inhibiting both HER2/neu receptor synthesis and activity. Cancer Res 2011; 71(4): 1454-64.
    • (2011) Cancer Res , vol.71 , Issue.4 , pp. 1454-1464
    • Inoue, S.1    Ding, H.2    Portilla-Arias, J.3    Hu, J.4    Konda, B.5    Fujita, M.6
  • 144
    • 84857089600 scopus 로고    scopus 로고
    • Nanobiopolymer for direct targeting and inhibition of EGFR expression in triple negative breast cancer
    • Inoue S, Patil R, Portilla-Arias J, Ding H, Konda B, Espinoza A, et al. Nanobiopolymer for direct targeting and inhibition of EGFR expression in triple negative breast cancer. PLoS One 2012; 7(2): e31070.
    • (2012) PLoS One , vol.7 , Issue.2
    • Inoue, S.1    Patil, R.2    Portilla-Arias, J.3    Ding, H.4    Konda, B.5    Espinoza, A.6
  • 145
    • 77957942614 scopus 로고    scopus 로고
    • A strategy for precision engineering of nanoparticles of biodegradable copolymers for quantitative control of targeted drug delivery
    • Liu Y, Li K, Liu B, Feng SS. A strategy for precision engineering of nanoparticles of biodegradable copolymers for quantitative control of targeted drug delivery. Biomaterials 2010; 31(35): 9145-55.
    • (2010) Biomaterials , vol.31 , Issue.35 , pp. 9145-9155
    • Liu, Y.1    Li, K.2    Liu, B.3    Feng, S.S.4
  • 148
    • 51449104994 scopus 로고    scopus 로고
    • A novel nanoparticle formulation for sustained paclitaxel delivery
    • Trickler WJ, Nagvekar AA, Dash AK. A novel nanoparticle formulation for sustained paclitaxel delivery. AAPS PharmSciTech 2008; 9(2): 486-93.
    • (2008) AAPS PharmSciTech , vol.9 , Issue.2 , pp. 486-493
    • Trickler, W.J.1    Nagvekar, A.A.2    Dash, A.K.3
  • 149
    • 33847155509 scopus 로고    scopus 로고
    • Nanoparticle-mediated drug delivery and gene therapy
    • Jin S, Ye K. Nanoparticle-mediated drug delivery and gene therapy. Biotechnol Prog 2007; 23(1): 32-41.
    • (2007) Biotechnol Prog , vol.23 , Issue.1 , pp. 32-41
    • Jin, S.1    Ye, K.2
  • 150
    • 77957065782 scopus 로고    scopus 로고
    • Towards a targeted multi-drug delivery approach to improve therapeutic efficacy in breast cancer
    • Wang B, Rosano JM, Cheheltani R, Achary MP, Kiani MF. Towards a targeted multi-drug delivery approach to improve therapeutic efficacy in breast cancer. Expert Opin Drug Deliv 2010; 7(10): 1159-73.
    • (2010) Expert Opin Drug Deliv , vol.7 , Issue.10 , pp. 1159-1173
    • Wang, B.1    Rosano, J.M.2    Cheheltani, R.3    Achary, M.P.4    Kiani, M.F.5
  • 151
    • 77954645526 scopus 로고    scopus 로고
    • The use of nanocarriers for drug delivery in cancer therapy
    • Khan DR. The use of nanocarriers for drug delivery in cancer therapy. J Cancer Sci Ther 2010; 2(3): 58-62.
    • (2010) J Cancer Sci Ther , vol.2 , Issue.3 , pp. 58-62
    • Khan, D.R.1
  • 152
    • 79960925147 scopus 로고    scopus 로고
    • Targeted drug delivery to tumors: Myths, reality and possibility
    • Bae YH, Park K. Targeted drug delivery to tumors: Myths, reality and possibility. J Control Release 2011; 153(3): 198-205.
    • (2011) J Control Release , vol.153 , Issue.3 , pp. 198-205
    • Bae, Y.H.1    Park, K.2
  • 153
    • 84862505006 scopus 로고    scopus 로고
    • The ubiquitin-like protein, ISG15, is a novel tumor-associated antigen for cancer immunotherapy
    • Wood LM, Pan ZK, Seavey MM, Muthukumaran G, Paterson Y. The ubiquitin-like protein, ISG15, is a novel tumor-associated antigen for cancer immunotherapy. Cancer Immunol Immunother 2012; 61(5): 689-700.
    • (2012) Cancer Immunol Immunother , vol.61 , Issue.5 , pp. 689-700
    • Wood, L.M.1    Pan, Z.K.2    Seavey, M.M.3    Muthukumaran, G.4    Paterson, Y.5
  • 155
    • 77955656948 scopus 로고    scopus 로고
    • Intratumoral delivery of encapsulated IL-12, IL-18 and TNF-alpha in a model of metastatic breast cancer
    • Sabel MS, Su G, Griffith KA, Chang AE. Intratumoral delivery of encapsulated IL-12, IL-18 and TNF-alpha in a model of metastatic breast cancer. Breast Cancer Res Treat 2010; 122(2): 325-36.
    • (2010) Breast Cancer Res Treat , vol.122 , Issue.2 , pp. 325-336
    • Sabel, M.S.1    Su, G.2    Griffith, K.A.3    Chang, A.E.4
  • 157
    • 79751472667 scopus 로고    scopus 로고
    • Tumor-derived JAGGED1 promotes osteolytic bone metastasis of breast cancer by engaging notch signaling in bone cells
    • Sethi N, Dai X, Winter CG, Kang Y. Tumor-derived JAGGED1 promotes osteolytic bone metastasis of breast cancer by engaging notch signaling in bone cells. Cancer Cell 2011; 19(2): 192-205.
    • (2011) Cancer Cell , vol.19 , Issue.2 , pp. 192-205
    • Sethi, N.1    Dai, X.2    Winter, C.G.3    Kang, Y.4
  • 158
    • 77955377644 scopus 로고    scopus 로고
    • Interference with Sin3 function induces epigenetic reprogramming and differentiation in breast cancer cells
    • Farias EF, Petrie K, Leibovitch B, Murtagh J, Chornet MB, Schenk T, et al. Interference with Sin3 function induces epigenetic reprogramming and differentiation in breast cancer cells. Proc Natl Acad Sci USA 2010; 107(26): 11811-6.
    • (2010) Proc Natl Acad Sci USA , vol.107 , Issue.26 , pp. 11811-11816
    • Farias, E.F.1    Petrie, K.2    Leibovitch, B.3    Murtagh, J.4    Chornet, M.B.5    Schenk, T.6
  • 160
    • 84864911902 scopus 로고    scopus 로고
    • AMD3100-mediated production of interleukin-1 from mesenchymal stem cells is key to chemosensitivity of breast cancer cells
    • Greco SJ, Patel SA, Bryan M, Pliner LF, Banerjee D, Rameshwar P. AMD3100-mediated production of interleukin-1 from mesenchymal stem cells is key to chemosensitivity of breast cancer cells. Am J Cancer Res 2011; 1(6): 701-15.
    • (2011) Am J Cancer Res , vol.1 , Issue.6 , pp. 701-715
    • Greco, S.J.1    Patel, S.A.2    Bryan, M.3    Pliner, L.F.4    Banerjee, D.5    Rameshwar, P.6
  • 162
    • 84866481797 scopus 로고    scopus 로고
    • Mesenchymal stem cell-derived interleukin-6 and vascular endothelial growth factor promote breast cancer cell migration
    • De Luca A, Lamura L, Gallo M, Maffia V, Normanno N. Mesenchymal stem cell-derived interleukin-6 and vascular endothelial growth factor promote breast cancer cell migration. J Cell Biochem 2012; 113(11): 3363-70.
    • (2012) J Cell Biochem , vol.113 , Issue.11 , pp. 3363-3370
    • de Luca, A.1    Lamura, L.2    Gallo, M.3    Maffia, V.4    Normanno, N.5
  • 163
    • 84856285214 scopus 로고    scopus 로고
    • Enhancing intracellular taxane delivery: Current role and perspectives of nanoparticle albuminbound paclitaxel in the treatment of advanced breast cancer
    • Guarneri V, Dieci MV, Conte P. Enhancing intracellular taxane delivery: Current role and perspectives of nanoparticle albuminbound paclitaxel in the treatment of advanced breast cancer. Expert Opin Pharmacother 2012; 13(3): 395-406.
    • (2012) Expert Opin Pharmacother , vol.13 , Issue.3 , pp. 395-406
    • Guarneri, V.1    Dieci, M.V.2    Conte, P.3
  • 164
    • 20444400599 scopus 로고    scopus 로고
    • Paclitaxel resistance in cells with reduced betatubulin
    • Wang Y, Cabral F. Paclitaxel resistance in cells with reduced betatubulin. Biochim Biophys Acta 2005; 1744(2): 245-55.
    • (2005) Biochim Biophys Acta , vol.1744 , Issue.2 , pp. 245-255
    • Wang, Y.1    Cabral, F.2
  • 165
    • 84873496961 scopus 로고    scopus 로고
    • Non-invasive imaging of PI3K/Akt/mTOR signalling in cancer
    • Gaikwad SM, Ray P. Non-invasive imaging of PI3K/Akt/mTOR signalling in cancer. Am J Nucl Med Mol Imaging 2012; 2(4): 418-31.
    • (2012) Am J Nucl Med Mol Imaging , vol.2 , Issue.4 , pp. 418-431
    • Gaikwad, S.M.1    Ray, P.2
  • 166
    • 38649085317 scopus 로고    scopus 로고
    • Fibronectin-mediated activation of Akt2 protects human ovarian and breast cancer cells from docetaxel-induced apoptosis via inhibition of the p38 pathway
    • Xing H, Cao Y, Weng D, Tao W, Song X, Wang W, et al. Fibronectin-mediated activation of Akt2 protects human ovarian and breast cancer cells from docetaxel-induced apoptosis via inhibition of the p38 pathway. Apoptosis 2008; 13(2): 213-23.
    • (2008) Apoptosis , vol.13 , Issue.2 , pp. 213-223
    • Xing, H.1    Cao, Y.2    Weng, D.3    Tao, W.4    Song, X.5    Wang, W.6
  • 167
    • 0035807219 scopus 로고    scopus 로고
    • Inhibition of BRCA1 leads to increased chemoresistance to microtubule-interfering agents, an effect that involves the JNK pathway
    • Lafarge S, Sylvain V, Ferrara M, Bignon YJ. Inhibition of BRCA1 leads to increased chemoresistance to microtubule-interfering agents, an effect that involves the JNK pathway. Oncogene 2001; 20(45): 6597-606.
    • (2001) Oncogene , vol.20 , Issue.45 , pp. 6597-6606
    • Lafarge, S.1    Sylvain, V.2    Ferrara, M.3    Bignon, Y.J.4
  • 168
    • 38449113305 scopus 로고    scopus 로고
    • Integrin-mediated adhesion: Tipping the balance between chemosensitivity and chemoresistance
    • Zutter MM. Integrin-mediated adhesion: Tipping the balance between chemosensitivity and chemoresistance. Adv Exp Med Biol 2007; 608: 87-100.
    • (2007) Adv Exp Med Biol , vol.608 , pp. 87-100
    • Zutter, M.M.1
  • 169
    • 84863625224 scopus 로고    scopus 로고
    • A CXCL1 paracrine network links cancer chemoresistance and metastasis
    • Acharyya S, Oskarsson T, Vanharanta S, Malladi S, Kim J, Morris PG, et al. A CXCL1 paracrine network links cancer chemoresistance and metastasis. Cell 2012; 150(1): 165-78.
    • (2012) Cell , vol.150 , Issue.1 , pp. 165-178
    • Acharyya, S.1    Oskarsson, T.2    Vanharanta, S.3    Malladi, S.4    Kim, J.5    Morris, P.G.6
  • 173
    • 0035845511 scopus 로고    scopus 로고
    • Gene expression patterns of breast carcinomas distinguish tumor subclasses with clinical implications
    • Sorlie T, Perou CM, Tibshirani R, Aas T, Geisler S, Johnsen H, et al. Gene expression patterns of breast carcinomas distinguish tumor subclasses with clinical implications. Proc Natl Acad Sci USA 2001; 98(19): 10869-74.
    • (2001) Proc Natl Acad Sci USA , vol.98 , Issue.19 , pp. 10869-10874
    • Sorlie, T.1    Perou, C.M.2    Tibshirani, R.3    Aas, T.4    Geisler, S.5    Johnsen, H.6
  • 174
    • 84861708138 scopus 로고    scopus 로고
    • Molecular biology in breast cancer: Intrinsic subtypes and signaling pathways
    • Eroles P, Bosch A, Perez-Fidalgo JA, Lluch A. Molecular biology in breast cancer: Intrinsic subtypes and signaling pathways. Cancer Treat Rev 2012; 38(6): 698-707.
    • (2012) Cancer Treat Rev , vol.38 , Issue.6 , pp. 698-707
    • Eroles, P.1    Bosch, A.2    Perez-Fidalgo, J.A.3    Lluch, A.4
  • 175
    • 83455236666 scopus 로고    scopus 로고
    • Basal breast cancer: A complex and deadly molecular subtype
    • Bertucci F, Finetti P, Birnbaum D. Basal breast cancer: A complex and deadly molecular subtype. Curr Mol Med 2012; 12(1): 96-110.
    • (2012) Curr Mol Med , vol.12 , Issue.1 , pp. 96-110
    • Bertucci, F.1    Finetti, P.2    Birnbaum, D.3
  • 176
    • 84861987023 scopus 로고    scopus 로고
    • Prognostic value of basal phenotype in HER2-overexpressing breast cancer
    • Bagaria SP, Ray PS, Wang J, Kropcho L, Chung A, Sim MS, et al. Prognostic value of basal phenotype in HER2-overexpressing breast cancer. Ann Surg Oncol 2012; 19(3): 935-40.
    • (2012) Ann Surg Oncol , vol.19 , Issue.3 , pp. 935-940
    • Bagaria, S.P.1    Ray, P.S.2    Wang, J.3    Kropcho, L.4    Chung, A.5    Sim, M.S.6
  • 177
    • 84855291245 scopus 로고    scopus 로고
    • Luminal-B breast cancer and novel therapeutic targets
    • Tran B, Bedard PL. Luminal-B breast cancer and novel therapeutic targets. Breast Cancer Res 2011; 13(6): 221.
    • (2011) Breast Cancer Res , vol.13 , Issue.6 , pp. 221
    • Tran, B.1    Bedard, P.L.2
  • 178
    • 83755174643 scopus 로고    scopus 로고
    • Molecular classification of estrogen receptor-positive/luminal breast cancers
    • Geyer FC, Rodrigues DN, Weigelt B, Reis-Filho JS. Molecular classification of estrogen receptor-positive/luminal breast cancers. Adv Anat Pathol 2012; 19(1): 39-53.
    • (2012) Adv Anat Pathol , vol.19 , Issue.1 , pp. 39-53
    • Geyer, F.C.1    Rodrigues, D.N.2    Weigelt, B.3    Reis-Filho, J.S.4
  • 180
    • 84872500139 scopus 로고    scopus 로고
    • Subtype-specific response to bevacizumab is reflected in the metabolome and transcriptome of breast cancer xenografts
    • Borgan E, Lindholm EM, Moestue S, Maelandsmo GM, Lingjaerde OC, Gribbestad IS, et al. Subtype-specific response to bevacizumab is reflected in the metabolome and transcriptome of breast cancer xenografts. Mol Oncol 2012; 7(1): 130-42.
    • (2012) Mol Oncol , vol.7 , Issue.1 , pp. 130-142
    • Borgan, E.1    Lindholm, E.M.2    Moestue, S.3    Maelandsmo, G.M.4    Lingjaerde, O.C.5    Gribbestad, I.S.6


* 이 정보는 Elsevier사의 SCOPUS DB에서 KISTI가 분석하여 추출한 것입니다.